Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
807.9 USD | +0.05% | +3.15% | +38.59% |
May. 28 | Annual sales of weight-loss drugs seen hitting $150 billion | RE |
May. 28 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
Evolution of the average Target Price on Eli Lilly and Company
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Eli Lilly and Company
Jefferies & Co. | |
Argus | |
Redburn Atlantic | |
China International Capital | |
JPMorgan Chase | |
Wolfe Research | |
Barclays | |
BMO Capital | |
Leerink Partners | |
Deutsche Bank Securities | |
Truist Securities | |
Goldman Sachs | |
Wells Fargo Securities | |
Morgan Stanley | |
UBS | |
BofA Securities | |
DZ Bank | |
JEFFERIES | Akash Tewari |
Cantor Fitzgerald | |
Morningstar | |
Guggenheim | |
Daiwa Securities | |
Berenberg Bank | |
Citigroup | |
Credit Suisse | |
HSBC | |
TD Cowen | |
SVB Securities LLC | |
Cowen | |
Mizuho Securities |
EPS Revisions
- Stock Market
- Equities
- LLY Stock
- Consensus Eli Lilly and Company